Pharmalittle: We’re reading about a weight loss pill, the FDA warning a compounder, and more
Viking Therapeutics shares surged Monday after early-stage data from its experimental oral obesity drug exceeded Wall Street expectations
Related Articles
Jam Session Registration
We are thrilled to share our new season of the Johns Hopkins Center for Health Equity (CHE) Jam Sessions! CHE invites speakers from a variety of research…
3 key issues to watch at the FDA as Trump takes office
Marty Makary and RFK Jr. are poised to make their marks on the FDA.
We wish we’d written that: STAT staffers share their favorite stories of 2024
In STAT’s “jealousy list” for 2024, STAT staffers explain what makes a selection of stories they read in other publications so compelling.
People from India remember life before the polio vaccine. They don’t want to go back
Indian-Americans who remember life before the polio vaccine are worried about what RFK Jr. could do in the U.S.
The biggest medical advances of 2024
The biggest medical advances of 2024 will be remembered as significant long into the future.
People from India remember life before the polio vaccine. They don’t want to go back
Indian-Americans who remember life before the polio vaccine are worried about what RFK Jr. could do in the U.S.
Global Reach
Bringing Radioligand Therapy (RLT) Clinical Trials to Your Fingertips We are uniquely positioned at the heart of Theranostics. We’re dedicated to increasing awareness about Theranostics…
Neumora’s antidepressant stumbles in first Phase 3 trial readout
A new depression treatment developed by startup Neumora Therapeutics failed in a Phase 3 clinical trial — the company’s first late-stage readout.
Concluding Thoughts on the Context of Physical Activity and Sedentary Behavior: Episode 6
In this conclusive sixth episode of our mini-series on the context of sedentary behavior and physical activity, we recap the importance of understanding thes…
Four digital health unicorns on what they expect in 2025
Top executives at Omada, Transcarent, Hinge Health and Maven Clinic reflect on the year that passed, and the year ahead for their companies.